Using negative control outcomes to identify biased study design: A self-controlled case series example. James Weaver 1,2.

Similar documents
Large scale analytics for electronic health records: Lessons from Observational Health Data Science and Informatics (OHDSI)

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?

A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions

The journey toward Clinical Characterization. Patrick Ryan, PhD Janssen Research and Development Columbia University Medical Center

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Supplementary Online Content

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

- Clinical Background, Motivation and my Experience at F2F meeting

The journey toward Population-level Effect Estimation. Martijn Schuemie, PhD Janssen Research and Development

Patrick Ryan, PhD Janssen Research and Development Columbia University Medical Center 12 July 2017

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

OHDSI Tutorial: Design and implementation of a comparative cohort study in observational healthcare data

Methodologies for CRNs: Can Statisticians, Epidemiologists, and Machine Learners Play in the Same Sand Box? Perspectives from OHDSI

Measure of Association Examples of measure of association

Modular Program Report

Drug Surveillance and Effectiveness Epidemiology Research - Questions to Ask your Epidemiologist

THIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY

Confounding in influenza VE studies in seniors, and possible solutions

EMR Big Data and Clinical Research. -Distributed Research Network and Common Data Model-

VACCINE ACTIVE SURVEILLANCE I

Plans for Surveillance of Acute Myocardial Infarction in users of Oral Anti Diabetes Drugs

Tuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data

Introducing the Flu and Other Respiratory Viruses Research (FOREVER) Cohort, a laboratory partnership for data sharing

Is There An Association?

Confounding Bias: Stratification

Self-controlled case-series method

ObservaBonal research results in literature

THE COST DRIVERS OF CANCER CARE

SUPPLEMENTAL MATERIALS

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10

Cost-Motivated Treatment Changes in Commercial Claims:

Basic Epidemiology: Study Types. Learning Objectives. The Five Ws of Epidemiology. At the end of this presentation, participants will be able to:

Appendix Identification of Study Cohorts

Reliable and reproducible effect size estimates at scale

Genomics Research. May 31, Malvika Pillai

Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data

Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data

Applying Hill's criteria as a framework for causal inference in observational data

The University of Mississippi School of Pharmacy

Generalizing the right question, which is?

MHSPHP Metrics Forum. Diabetes.

Evidence-Based Review Process to Link Dietary Factors with Chronic Disease Case Study: Cardiovascular Disease and n- 3 Fatty Acids

Zhao Y Y et al. Ann Intern Med 2012;156:

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source

Osler Journal Club Outcomes Research

The Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD

Week 11: March 11 to March 17, 2018

Week 15: April 8 to April 14, 2018

Quality measures a for measurement year 2016

PROTECT: Work Package 6 PROTECT: An Innovative Public-Private Partnership for New Methodologies in Pharmacovigilance and Pharmacoepidemiology

Presenter Disclosure Information

Weekly Influenza Surveillance Summary

10/29/2014. Influenza Surveillance and Reporting. Outline

Mortality following acute myocardial infarction (AMI) in

MAKING THE NSQIP PARTICIPANT USE DATA FILE (PUF) WORK FOR YOU

Clinical Outcomes Among Vascular Procedure Patients Receiving Suture-mediated vs Surgical Cutdown for Closure of Large-bore Arterial Access

Performance Analysis:

Main objective of Epidemiology. Statistical Inference. Statistical Inference: Example. Statistical Inference: Example

Incorporating Clinical Information into the Label

Epidemiologic study designs

ethnicity recording in primary care

Alberta Health. Seasonal Influenza in Alberta. 2016/2017 Season. Analytics and Performance Reporting Branch

D:A:D: Cumulative Exposure to DRV/r Increase MI Risk

Efficiency Methodology

Lecture 2. Key Concepts in Clinical Research

Evolution of Active Surveillance: An Industry Perspective

IHA P4P Measure Manual Measure Year Reporting Year 2018

Medicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment

Comparing Complex Diagnoses: A Formative Evaluation of the Heart Disease Program

IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid

Validating and Grouping Diagnosis

ACO Congress Conference Pre Session Clinical Performance Measurement

MiPCT Dashboard. User Guide RELEA S E Document File Name MiPCT_Dashboard_UG_v20_00.docx. Document Author Kendra Mallon. Created October 9, 2017

DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA

RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION

Communicable Disease. Introduction

OHDSI: Drawing reproducible conclusions from observational clinical data

Answer keys for Assignment 4: Measures of disease frequency

Institute of Medical Epidemiology, Biostatistics, and Informatics, University of Halle-Wittenberg, Halle (Saale) 2

Who's Driving the DRG Bus: Selecting the Appropriate Principal Diagnosis

Transfusion & Mortality. Philippe Van der Linden MD, PhD

Health Services Utilization and Medical Costs Among Medicare Atrial Fibrillation Patients / September 2010

Dabigatran Evidence in Real Practice

Please evaluate this material by clicking here:

Policy Brief June 2014

4Q17 Core Measures and 2Q18 MBQIP Data

Studies of Guillain-Barré syndrome (GBS) after influenza vaccination

Let s Talk about Nutrition: Communication Skills for Health Care Professionals Topic 39

Study Exposures, Outcomes:

Epidemiologic Methods and Counting Infections: The Basics of Surveillance

Flu Vaccination. John Hann, MD UC Irvine Health

QUASI-EXPERIMENTAL HEALTH SERVICE EVALUATION COMPASS 1 APRIL 2016

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018

Monitoring the HCV care cascade to inform public health action

Fixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University

Depression and Anxiety Relative Risks in Women Newly Diagnosed with Vulvovaginal Atrophy and Dyspareunia

Supplementary Online Content

Transcription:

Using negative control outcomes to identify biased study design: A self-controlled case series example James Weaver 1,2 1Janssen Research & Development, LLC, Raritan, NJ, USA 2 Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA jweave17@its.jnj.com

Agenda I. Introduction II. Self-controlled case series for population-level effect estimation III. Methods IV. Results V. Discussion OHDSI Community Call 2018/05/29 2

I. Introduction Observational data management Methodological development Open-source analytics development Clinical applications Clinical characterization Population-level effect estimation Patient-level prediction OHDSI Community Call 2018/05/29 3

I. Introduction Observational data management Methodological development Open-source analytics development Clinical applications Clinical characterization Population-level effect estimation Patient-level prediction OHDSI Community Call 2018/05/29 4

I. Introduction Observational data management Methodological development Open-source analytics development Clinical applications Clinical characterization Population-level effect estimation Patient-level prediction OHDSI Community Call 2018/05/29 5

I. Introduction Clinical application Does influenza cause acute myocardial infarction? IRR = 6.05 (3.86 9.50) Population-level effect estimation (PLE) Self-controlled case series (SCCS) https://www.bmj.com/content/354/bmj.i4515 BMJ 2016;354:i4515 OHDSI Community Call 2018/05/29 6

II. SCCS for PLE Population-level effect estimation Epidemiologic methods for causal inference Estimating unbiased, average treatment effect Goal: compare outcomes between an exposed population and its counterfactual approximation OHDSI Community Call 2018/05/29 7

II. SCCS for PLEE Population-level effect estimation Epidemiologic methods for causal inference Estimating unbiased, average treatment effect Goal: compare outcomes between an exposed population and its counterfactual approximation OHDSI Community Call 2018/05/29 8

II. SCCS for PLEE Self-controlled case series Effect estimation: does T cause O? Compares outcomes within persons during time periods of differing risk (e.g. exposed time vs unexposed time) Unexposed time = counterfactual approximation of exposed population OHDSI Community Call 2018/05/29 9

II. SCCS for PLEE Self-controlled case series Self-controlled: a patient is their own control Cases only: intersection of exposed and outcome cohorts Compares outcome incidence during a risk period (e.g. exposed time) to other time (e.g. unexposed time) during study window When events occur relative to risk period given that event(s) occurred OHDSI Community Call 2018/05/29 10

III. Methods Kwong et al., N Engl J Med 378;4:345-353. T: Highly specific, laboratory-confirmed influenza diagnosis Flu and Other Respiratory Viruses Research Cohort Specimens from routine clinical care, research, outbreak investigation O: Primary, inpatient myocardial infarction (not same visit as flu dx) Discharge Abstract Database, National Ambulatory Care Reporting System, Same-Day Surgery Database, Ontario Health Insurance Plan Risk interval: 7 days following influenza diagnosis Study period: 1 year before to 1 year after influenza diagnosis Multiple sensitivity analyses OHDSI Community Call 2018/05/29 11

III. Methods Kwong et al., N Engl J Med 378;4:345-353. OHDSI Community Call 2018/05/29 12

IV. Methods Best faith replication T: Visit occurrence with influenza diagnosis, no outcome code, no influenza diagnoses in last 60 days Truven Health MarketScan Commercial Claims and Encounters Database Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database O: Inpatient visit occurrence with primary, acute myocardial infarction (not same visit as flu dx) Risk interval: start - influenza visit end, influenza visit start + 7 days Study period: 1 year before to 1 year after influenza diagnosis Multiple sensitivity analyses Negative control outcomes: lung cancer, ingrowing nail, T2DM, renal impairment, acute liver injury, HIV, anemia, depression OHDSI Community Call 2018/05/29 13

IV. Results CCAE Kwong et al. Replication Outcome IRR 95% CI lower 95% CI upper IRR 95% CI lower 95% CI upper AMI 6.05 3.86 9.50 T2DM NULL - - Lung cancer Ingrowing nail Renal impairment Acute liver injury HIV Anemia Depression OHDSI Community Call 2018/05/29 14

IV. Results CCAE Kwong et al. Replication Outcome IRR 95% CI lower 95% CI upper IRR 95% CI lower 95% CI upper AMI 6.05 3.86 9.50 3.76 3.16 4.43 T2DM NULL - - 5.36 4.82 5.95 Lung cancer Ingrowing nail Renal impairment Acute liver injury HIV Anemia Depression OHDSI Community Call 2018/05/29 15

IV. Results CCAE Kwong et al. Replication Outcome IRR 95% CI lower 95% CI upper IRR 95% CI lower 95% CI upper AMI 6.05 3.86 9.50 3.76 3.16 4.43 T2DM NULL - - 5.36 4.82 5.95 Lung cancer 4.02 3.07 5.16 Ingrowing nail 5.93 1.44 16.05 Renal impairment 9.45 8.74 10.20 Acute liver injury 15.94 12.69 19.76 HIV 8.91 6.42 12.03 Anemia 5.08 4.26 6.01 Depression 1.22 1.05 1.40 OHDSI Community Call 2018/05/29 16

V. Discussion Replication showed similar acute myocardial infarction results across all analysis variants Lesser magnitude of positive effect Replication showed conflicting T2DM results across all analysis variants Strong positive effect rather than null OHDSI Community Call 2018/05/29 17

V. Discussion Replication unable to replicate highly specific, lab confirmed influenza exposure definition Ontario team re-executed T2DM analysis with influenza exposure definition using administrative data and found increased effect Decreased specificity influenza definition Influenza false positives responsible T2DM cases? Inconsistent with replication findings of reduced MI effect Berkon s bias hospitalized patients at greater outcome risk Test by restricting laboratory influenza definition to IP, OP OHDSI Community Call 2018/05/29 18

V. Discussion What this work demonstrates: Value of negative controls as a diagnostic test For assessing trust in main results Literature: https://www.ncbi.nlm.nih.gov/pubmed/23900808 https://www.ncbi.nlm.nih.gov/pubmed/26970249 https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5856503/ What this work does not demonstrate: The true effect of influenza on myocardial infarction OHDSI Community Call 2018/05/29 19

V. Discussion Next steps: find a design and specification that produces a null association between influenza and negative controls Executed cohort study assessing the hazards of first occurrence, primary inpatient AMI and negative controls among patients with influenza compared to 1:1 propensity scored matched patients with a cold during 7 days time-at-risk Results roughly the same OHDSI Community Call 2018/05/29 20

V. Discussion Challenge: Can someone in the OHDSI community produce a design specification that estimates a null association between influenza and negative controls? https://github.com/ohdsi/studyprotocolsandbox/tree/master/fluamisccs OHDSI Community Call 2018/05/29 21

V. Discussion Questions jweave17@its.jnj.com OHDSI Community Call 2018/05/29 22